{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:40Z","timestamp":1793332600805,"version":"4.5.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Various pharmacotherapies exist for heart failure with preserved ejection fraction (HFpEF), but with unclear comparative efficacy. We searched EMBASE, Medline, and Cochrane Library from inception through August 2021 for all randomized clinical trials in HFpEF (EF &gt;40%) that evaluated beta-blockers, mineralocorticoid receptor antagonist (MRA), angiotensin-converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Outcomes assessed were cardiovascular mortality, all-cause mortality, and HF hospitalization. A frequentist network meta-analysis was performed with a random-effects model. We included 22 randomized clinical trials (30,673 participants; mean age = 71.7\u2009\u00b1\u20094.2 years; females = 49.3\u2009\u00b1\u20097.7%; median follow-up = 24.4\u2009\u00b1\u200911.1 months). Compared with placebo, there was no statistically significant difference in cardiovascular mortality [beta-blockers; odds ratio (OR) 0.79 (0.46\u20131.34), MRA; OR 0.90 (0.70\u20131.14), ACE OR 0.95 (0.59\u20131.53), ARB; OR 1.02 (0.87\u20131.19), ARNI; OR 0.97 (0.74\u20131.26) and SGLT2i; OR 1.00 (0.84\u20131.18)] or all-cause mortality [beta blockers; OR 0.75 (0.54\u20131.04), MRA; OR 0.90 (0.75\u20131.08) ACE; OR 1.05 (0.71\u20131.54), ARB; OR 1.03 (0.91\u20131.15), ARNI; OR 0.99 (0.82\u20131.20) and SGLT2i; OR 1.00 (0.89\u20131.13)]. The certainty in these estimates was low or very low. There was a significantly reduction in HF hospitalization with the use of SGLT2i [OR 0.71 (0.62\u20130.82), moderate certainty], ARNI [OR 0.77 (0.63\u20130.94), low certainty], and MRA [OR 0.81 (0.66\u20130.98), moderate certainty]; with corresponding <jats:italic toggle=\"yes\">P<\/jats:italic> scores of 0.84, 0.68, and 0.58, respectively. In HFpEF, the use of beta-blockers, MRA, ACE\/ARB\/ARNI, or SGLT2i was not associated with improved cardiovascular or all-cause mortality. SGLT2i, ARNI, and MRA reduced the risk of HF hospitalizations.<\/jats:p>","DOI":"10.1097\/crd.0000000000000484","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T15:00:33Z","timestamp":1672239633000},"page":"114-123","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1097","volume":"32","author":[{"given":"Jayakumar","family":"Sreenivasan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaqib","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lloji","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvashi","family":"Hooda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg M.","family":"Lanier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gass","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar R.","family":"Desai","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Panza","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective.","volume":"124","author":"Pfeffer MA","year":"2019","journal-title":"Circ Res"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1161\/01.CIR.98.21.2282","article-title":"Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.","volume":"98","author":"Senni","year":"1998","journal-title":"Circulation"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","article-title":"Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort.","volume":"33","author":"Vasan","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250619","first-page":"Cd012721","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.","volume":"6","author":"Martin","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","article-title":"Updated method guidelines for systematic reviews in the cochrane collaboration back review group.","volume":"28","author":"van Tulder","year":"2003","journal-title":"Spine"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1161\/CIR.0000000000000523","article-title":"Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American Heart Association.","volume":"136","author":"Rao","year":"2017","journal-title":"Circulation"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial.","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory.","volume":"3","author":"Rucker","year":"2012","journal-title":"Res Synth Methods"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jrsm.1143","article-title":"Automated drawing of network plots in network meta-analysis.","volume":"7","author":"Rucker","year":"2016","journal-title":"Res Synth Methods"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods.","volume":"15","author":"Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jrsm.1410","article-title":"Beyond the forest plot: the drapery plot.","volume":"12","author":"Rucker","year":"2021","journal-title":"Res Synth Methods"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks.","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence.","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9149(97)00320-2","article-title":"Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors.","volume":"80","author":"Aronow","year":"1997","journal-title":"Am J Cardiol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejheart.2004.02.003","article-title":"Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).","volume":"6","author":"Bergstr\u00f6m","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/eurheartj\/ehi735","article-title":"Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy.","volume":"27","author":"Ghio","year":"2006","journal-title":"Eur Heart J"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results.","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.","volume":"54","author":"Mak","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/jgs.14940","article-title":"Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction.","volume":"65","author":"Upadhya","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0002-9149(98)00174-X","article-title":"Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction.","volume":"81","author":"Aronow","year":"1998","journal-title":"Am J Cardiol"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study.","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1025387702212","article-title":"The effect of quinapril on functional status of elderly patients with diastolic heart failure.","volume":"17","author":"Zi","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction.","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet (London, England)"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction.","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertension"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2014.12.017","article-title":"The hospitalization burden and post-hospitalization mortality risk in heart failure with preserved ejection fraction: results from the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).","volume":"3","author":"Carson","year":"2015","journal-title":"JACC Heart failure"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:02:48Z","timestamp":1750348968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000484","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}